Skip to main content
. Author manuscript; available in PMC: 2014 May 14.
Published in final edited form as: Nature. 2013 May 29;498(7454):325–331. doi: 10.1038/nature12204

Figure 5. Pharmacological inhibition of the MAPK pathway decreases ATXN1 level.

Figure 5

a, Western blots and quantifications show a decrease in ATXN1 levels from Daoy mRFP– ATXN1(82Q) cells upon treatment with the indicated inhibitors (PD184352, 10 μM; GW5704, 10 μM; Ro-31-8220, 1 μM; H89, 5 μM). Error bars indicate s.e.m. from three independent experiments. b, c, Dose–response graphs show a decrease in Atxn1 levels from mouse cerebellar slices upon treatment with the indicated inhibitors. Error bars indicate s.e.m. from three independent experiments. *P < 0.05, **P < 0.01, Student’s t-test. DMSO, dimethylsulphoxide.